April 26, 2018 – Toronto, Ontario – Delivra Corp. (“Delivra”, or “the Company”) today announced that its R&D, pre-clinical and clinical teams have successfully developed and tested line-extension products using its precision topical delivery system platform, DelivraTM. These consumer product initiatives include cannabis-related products at both the over-the-counter (“OTC”) and prescription levels. With the assistance and support of Emergence, Canada’s virtual incubator that supports the growth of innovative bioscience and food sector ventures, Delivra has developed its strategy and executed on ready to use products for OTC line extensions that will compliment its already existing successful LivRelief products, and is ready for the upcoming legalization of cannabis with its vast array of cannabis-related products for third party distributors for different disease indications.

Overall, the evaluation strategies affirms that Delivra’s novel proprietary delivery system can achieve further gains within the chronic pain and sleep/anxiety markets. Importantly, current sales and gross margins outperform several competing brand names in the pain segment and an acceleration of LivRelief’s successful suite of products is expected to be met with success. This acceleration of LivRelief sales growth in the topical OTC category will involve additional unique SKUs at existing accounts and an enhancement of the distribution channels, which is now over 5,200 pharmacy/grocery and natural products stores.

“Delivra will continue to implement a strategy to develop a multi-formulation/multi-size portfolio, while maintaining and strengthening its fundamental natural brand position through scientific and natural ingredient synergies, while continuing to increase our presence at the prescription level. As part of our newest marketing initiative, we will focus on further increasing brand awareness, bolster marketing and distribution efforts and providing innovative packaging of our currently successful suite of consumer products. Driving increased sales with a proprietary suite of innovative products remains one of our key focuses. This reaffirms our commitment to further develop and commercialize our expanding pipeline of cream-based therapeutics across Canada and we thank Emergence for their ongoing support of Delivra and its vision,” said Dr. Joseph Gabriele, CEO of Delivra.


Delivra Corp. is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Hamilton, Ontario and has a research and development laboratory in Charlottetown, PEI.

Further information on Delivra can be found at www.delivracorp.com and www.livrelief.com.


Emergence is a virtual incubator that supports the formation and growth of innovative bioscience and food sector ventures. Emergence clients benefit from access to business, technical, scientific and regulatory support services customized to meet their individual needs. This includes one-on-one and team-based mentorship; third-party consulting services; market research; legal, IP, insurance, tax and financial expertise from a network of professional service provider partners; and support accessing international networks and public and private funding and investment opportunities. As a virtual incubator Emergence serves high-potential companies wherever they are located in Canada; while also providing a “soft landing” for innovative international bioscience ventures seeking to start-up or establish themselves in, or expand into, Canada.

Further information on Emergence can be found at https://emergencebioincubator.com/

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute “forward-looking statements”, which are not comprised of historical facts. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “intends”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”, and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the Company’s revenues and financial performance; the Company’s drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Delivra to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management’s expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Delivra will continue substantially in the ordinary course and will be favourable to Delivra; that the Company will continue to complete orders with existing customers and control product pricing and expenses that clinical testing results will justify commercialization of the Company’s drug candidates; that Delivra will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Delivra will be able to find suitable partners for development and commercialization of its products and intellectual property on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: the ability of the Company to maintain existing product sales with current customers at existing product pricing and expenses; uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the ability of the Company to generate sales and profits; the Company’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Delivra’s public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Delivra disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Dr. Joseph Gabriele

Chief Executive Officer



Investor Relations:

Joanna Longo


416-238-1414 x233